These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8975096)

  • 21. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.
    Raderer M; Hamilton G; Kurtaran A; Valencak J; Haberl I; Hoffmann O; Kornek GV; Vorbeck F; Hejna MH; Virgolini I; Scheithauer W
    Br J Cancer; 1999 Feb; 79(3-4):535-7. PubMed ID: 10027326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.
    Maiza JC; Castillo-Ros S; Matta M; Bennet A; Caron P
    Pituitary; 2012 Dec; 15 Suppl 1():S23-7. PubMed ID: 21221819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors.
    Zheng N; Dai W; Zhang H; Wang X; Wang J; Zhang X; Wang K; Li J; Zhang Q
    J Drug Target; 2015 Jan; 23(1):67-78. PubMed ID: 25366085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The quality of life in acromegaly.
    Pantanetti P; Sonino N; Arnaldi G; Boscaro M
    J Endocrinol Invest; 2003; 26(8 Suppl):35-8. PubMed ID: 15233210
    [No Abstract]   [Full Text] [Related]  

  • 26. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution.
    Gillespie TJ; Erenberg A; Kim S; Dong J; Taylor JE; Hau V; Davis TP
    J Pharmacol Exp Ther; 1998 Apr; 285(1):95-104. PubMed ID: 9535998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of lanreotide for the treatment of gastrointestinal fistulae.
    Clive K; Hardin M; White C; Larson C; Oh J; Cohn S
    Ann Surg; 2011 Jan; 253(1):211; author reply 211-2. PubMed ID: 21135689
    [No Abstract]   [Full Text] [Related]  

  • 29. Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC).
    Mitsogiannis IC; Skolarikos A; Deliveliotis C
    Expert Opin Pharmacother; 2009 Feb; 10(3):493-501. PubMed ID: 19191684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats.
    Molina-Trinidad EM; de Murphy CA; Jung-Cook H; Stack EM; Pedraza-Lopez M; Morales-Marquez JL; Serrano GV
    J Pharm Pharmacol; 2010 Apr; 62(4):456-61. PubMed ID: 20604834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide.
    Raderer M; Hejna MH; Kurtaran A; Kornek GV; Valencak JB; Oberhuber G; Vorbeck F; Virgolini I; Scheithauer W
    Am J Gastroenterol; 1999 Jan; 94(1):278-9. PubMed ID: 9934776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medical treatment of acromegaly].
    Lorcy Y
    Ann Endocrinol (Paris); 2005 Feb; 66(1):55-8. PubMed ID: 15798597
    [No Abstract]   [Full Text] [Related]  

  • 33. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma.
    Vitale G; Tagliaferri P; Caraglia M; Rampone E; Ciccarelli A; Bianco AR; Abbruzzese A; Lupoli G
    J Clin Endocrinol Metab; 2000 Mar; 85(3):983-8. PubMed ID: 10720027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Peritoneal mesothelioma: long survival with intraperitoneal chemotherapy, lanreotide and mucolytics].
    Montmayeur G; Thivat E; Gimbergues P; Dib M; Leheurteur M; Curé H; Chollet P; Durando X
    Gastroenterol Clin Biol; 2008 Oct; 32(10):874-5. PubMed ID: 18353584
    [No Abstract]   [Full Text] [Related]  

  • 35. Insulin-like factor 3 plasma levels in acromegaly before and after somatostatin analog treatment.
    Rossato M; Dassie F; Silvestrin V; Martini C; Vettor R; Maffei P
    Endocrine; 2015 Mar; 48(2):705-8. PubMed ID: 24917446
    [No Abstract]   [Full Text] [Related]  

  • 36. Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases.
    Sun L; Yu CY; Mackey LV; Coy DH
    Curr Top Med Chem; 2015; 16(2):133-40. PubMed ID: 26126910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of pasireotide in the treatment of acromegaly.
    Tritos NA
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):855-6. PubMed ID: 25260837
    [No Abstract]   [Full Text] [Related]  

  • 38. Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly.
    Pereira EA; Turner MR; Wass JA; Talbot K
    Amyotroph Lateral Scler; 2010; 11(1-2):255-7. PubMed ID: 19634028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pasireotide for the treatment of acromegaly.
    Wildemberg LE; Gadelha MR
    Expert Opin Pharmacother; 2016; 17(4):579-88. PubMed ID: 26808354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapy: pasireotide for uncontrolled acromegaly-new phase III trial data.
    Sargent J
    Nat Rev Endocrinol; 2014 Dec; 10(12):700. PubMed ID: 25311393
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.